Dogwood Therapeutics, Inc (NASDAQ:DWTX) Sees Significant Increase in Short Interest

Dogwood Therapeutics, Inc (NASDAQ:DWTX) saw a significant increase in short interest in April. As of April 30th, there was short interest totaling 125,511 shares, an increase of 169.5% from the April 15th total of 46,578 shares. Approximately 0.4% of the company’s shares are short sold. Based on an average daily volume of 131,384 shares, the days-to-cover ratio is presently 1.0 days.

Institutional Trading of Dogwood Therapeutics

An institutional investor recently bought a new position in Dogwood Therapeutics stock. Marshall Wace LLP purchased a new stake in Dogwood Therapeutics, Inc (NASDAQ:DWTX) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned about 0.51% of Dogwood Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 9.05% of the company’s stock.

Dogwood Therapeutics Stock Performance

Shares of DWTX stock traded down $0.15 during trading on Friday, reaching $1.83. The company’s stock had a trading volume of 114,856 shares, compared to its average volume of 119,906. Dogwood Therapeutics has a one year low of $1.28 and a one year high of $9.50. The business has a fifty day moving average price of $2.09 and a 200-day moving average price of $3.64.

Dogwood Therapeutics (NASDAQ:DWTX) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.07. Equities research analysts expect that Dogwood Therapeutics will post -0.93 EPS for the current fiscal year.

Analysts Set New Price Targets

DWTX has been the topic of several recent analyst reports. Weiss Ratings downgraded shares of Dogwood Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, April 27th. HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of Dogwood Therapeutics in a research report on Monday, April 27th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $12.00.

About Dogwood Therapeutics

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.